OpGen Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

John Tan

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	4.5yrs

Recente managementupdates

Recent updates

CEO

John Tan (34 yo)

less than a year

Tenure

Mr. Honjian Tan, also known as John, is Chief Executive Officer & Chairman of OpGen, Inc. from August 2, 2024. Mr. Tan is President, Chief Executive Officer, CFO, Secretary & Chairman of UBuyHoldings, Inc....

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Honjian Tan	CEO & Chairman	less than a year	geen gegevens	geen gegevens
James Snyder	Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens
Debra Goff	Member of Clinical Advisory Board	8.7yrs	geen gegevens	geen gegevens
Stefan Riedel	Member of Clinical Advisory Board	8.7yrs	geen gegevens	geen gegevens
Patricia Simner	Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens
Christian-Laurent Bonte	Independent Director	less than a year	geen gegevens	geen gegevens

4.5yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van 0A8L wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).

OpGen Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Opgen, Inc. Announces Chief Executive Officer Changes

OpGen, Inc., Annual General Meeting, Jun 09, 2022

Recent updates

OpGen Receives a Letter from the Nasdaq Hearings Panel Determines to Deny its Request for Continued Listing on Nasdaq

OpGen, Inc.(OTCPK:OPGN) dropped from S&P TMI Index

OpGen, Inc.(OTCPK:OPGN) dropped from NASDAQ Composite Index

OpGen, Inc. announced delayed 10-Q filing

OpGen Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on Nasdaq

Nasdaq Hearings Panel Grants Extension to OpGen, to Regain Compliance by July 8, 2024

OpGen Receives Notice from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5250(c)(1) Due to Not Filing its Quarterly Report on Form 10-Q for the Period Ended March 31, 2024

OpGen, Inc. announced delayed 10-Q filing

OpGen, Inc. Announces 1-For-10 Reverse Stock Split to Regain Compliance with the Nasdaq Capital Market’s Minimum Bid Price Listing Requirement of $1.00 Per Share

OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K

OpGen, Inc. announced delayed annual 10-K filing

Opgen, Inc. Announces Chief Executive Officer Changes

New major risk - Revenue and earnings growth

OpGen Submits A Request for A Hearing Before the Panel, Which Request Stayed Any Suspension or Delisting Action by Nasdaq At Least Until the Hearing Process Concludes and Any Extension Granted by the Panel Expires

Third quarter 2023 earnings released: US$0.46 loss per share (vs US$5.92 loss in 3Q 2022)

OpGen, Inc. announced that it expects to receive $1 million in funding

OpGen, Inc. to Report Q2, 2023 Results on Aug 10, 2023

OpGen Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement

OpGen, Inc. to Report Q1, 2023 Results on May 15, 2023

OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.

OpGen, Inc. Announces Preliminary Unaudited Revenue for 2022

OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million.

OpGen, Inc Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel

OpGen, Inc. Reports Goodwill Impairment Charge for the Third Quarter Ended September 30, 2022

OpGen, Inc. to Report Q3, 2022 Results on Nov 10, 2022

OpGen, Inc. to Report Q3, 2022 Results on Nov 10, 2022

OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $3.38 million.

OpGen, Inc. Announces Successful Completion of Clinical Trial Enrollment for Unyvero Urinary Tract Infection Panel

Nasdaq Grants OpGen 180-Day Extension to Meet Minimum Bid Price Requirement

Opgen, Inc. Launches Ares Sequencing Services in the U.S. from Its Rockville, Maryland Laboratory

OpGen, Inc. Provides Revenue Guidance for Fiscal Year 2022

OpGen, Inc. to Report Q2, 2022 Results on Aug 11, 2022

OpGen, Inc. Announces Publication of Results of Unyvero Hospitalized Pneumonia (Hpn) Panel for Detection of Bacterial Respiratory Tract Pathogens from Serial Specimens Collected from Hospitalized Covid-19 Patients

OpGen, Inc. Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia Panel in the Lancet Respiratory Medicine

OpGen, Inc. Provides Earnings Guidance for the Year 2022

OpGen, Inc., Annual General Meeting, Jun 09, 2022

OpGen, Inc. Announces Interim Analysis Results from Clinical Trial for Unyvero Urinary Tract Infection Panel

OpGen, Inc. Provides Revenue Guidance for the Year 2022

OpGen, Inc. Announces Publication of Results from the Acuitas AMR Gene Panel Multicenter Clinical Trial in the Journal of Clinical Microbiology

OpGen, Inc. Submits Updated 510(k) Summary to FDA For Acuitas AMR Gene Panel for Isolates

First quarter 2021 earnings released: US$0.50 loss per share (vs US$0.53 loss in 1Q 2020)

CEO

Tenure

Bestuursleden

Gemiddelde duur